| abstract |
5- [3- (2,5-Dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1, which is an inhibitor of catechol-O-methyltransferase (COMT) A novel polymorph of 2,4] oxadiazol-5-yl] -3-nitrobenzene-1,2-diol, a process for its production, and a pharmaceutical composition containing the novel polymorph as an active pharmaceutical ingredient. 5- [3- (2,5-Dichloro-, characterized in that the X-ray powder diffraction pattern shows the following 2θ angles: 6.6, 13.2, 17.9 and 23.8. Crystal modification of 4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4] oxadiazol-5-yl] -3-nitrobenzene-1,2-diol. And a pharmaceutical composition comprising a pre-crystal modification. [Selection figure] None |